Defining Progression in Metastatic Kidney Cancer
3 Visualizzazioni
• 06/26/23
0
0
Incorporare
administrator
Iscritti
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti